New synthetic cannabinoid compounds designed to study the CB1 receptor
Researchers created new adamantyl-based cannabinoid compounds that bind strongly to the CB1 receptor and may serve as useful tools for studying how the endocannabinoid system works.
Quick Facts
What This Study Found
Scientists synthesized a series of novel cannabinoid compounds built on an adamantyl (diamond-shaped carbon cage) framework attached to the structure of natural THC. Among these, compound AM4054 showed high affinity for the CB1 receptor and acted as a full agonist, while compound AM4089 showed partial agonist activity with selectivity for CB1 over CB2.
In rat models measuring hypothermia and pain response, the in vivo effects matched the in vitro binding profiles. The adamantyl-substituted compounds showed improved pharmacological profiles compared to the traditionally used dimethylheptyl analogs.
Key Numbers
Two lead compounds emerged: AM4054 (full CB1 agonist with high affinity) and AM4089 (partial agonist with moderate CB1/CB2 selectivity). In vivo results in rat models were consistent with in vitro binding data.
How They Did This
Researchers designed and synthesized a series of tricyclic cannabinoid analogues with modifications at the C-3 and 9-NAH (northern aliphatic hydroxyl) positions. Compounds were tested for receptor binding affinity (CB1 and CB2), functional activity using cAMP assays, and in vivo effects in rat models of hypothermia and analgesia.
Why This Research Matters
Selective receptor probes are critical tools for understanding how the endocannabinoid system functions. These compounds help researchers study CB1 receptor signaling with greater precision than natural cannabinoids, which bind to multiple targets.
The Bigger Picture
This type of medicinal chemistry work provides the research tools needed to dissect cannabinoid receptor function. Understanding how structural modifications affect receptor binding and activity helps guide the development of potential therapeutics targeting the endocannabinoid system.
What This Study Doesn't Tell Us
These are laboratory-synthesized research compounds, not medications. In vivo testing was limited to rat models of hypothermia and analgesia. Long-term safety, human pharmacokinetics, and therapeutic potential were not assessed.
Questions This Raises
- ?Could adamantyl-based cannabinoids eventually lead to therapeutic applications?
- ?How do these compounds perform in more complex behavioral models?
- ?What is the abuse potential of full CB1 agonists with this structural framework?
Trust & Context
- Key Stat:
- Novel compounds showed improved pharmacological profiles over traditional analogs
- Evidence Grade:
- Preclinical medicinal chemistry study with in vitro and animal model validation. No human data.
- Study Age:
- Published in 2013. These research tools continue to be used in endocannabinoid system studies.
- Original Title:
- Novel adamantyl cannabinoids as CB1 receptor probes.
- Published In:
- Journal of medicinal chemistry, 56(10), 3904-21 (2013)
- Authors:
- Thakur, Ganesh A(10), Bajaj, Shama(2), Paronis, Carol, Peng, Yan, Bowman, Anna L, Barak, Lawrence S, Caron, Marc G, Parrish, Demon, Deschamps, Jeffrey R, Makriyannis, Alexandros
- Database ID:
- RTHC-00743
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What are adamantyl cannabinoids?
They are synthetic compounds that combine a diamond-shaped carbon cage (adamantane) with the basic structure of THC, designed to bind with high affinity and selectivity to cannabinoid receptors for research purposes.
Are these the same as synthetic cannabinoids sold as street drugs?
No. These are research-grade compounds created for controlled laboratory studies of cannabinoid receptor function, not intended for recreational use.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00743APA
Thakur, Ganesh A; Bajaj, Shama; Paronis, Carol; Peng, Yan; Bowman, Anna L; Barak, Lawrence S; Caron, Marc G; Parrish, Demon; Deschamps, Jeffrey R; Makriyannis, Alexandros. (2013). Novel adamantyl cannabinoids as CB1 receptor probes.. Journal of medicinal chemistry, 56(10), 3904-21. https://doi.org/10.1021/jm4000775
MLA
Thakur, Ganesh A, et al. "Novel adamantyl cannabinoids as CB1 receptor probes.." Journal of medicinal chemistry, 2013. https://doi.org/10.1021/jm4000775
RethinkTHC
RethinkTHC Research Database. "Novel adamantyl cannabinoids as CB1 receptor probes." RTHC-00743. Retrieved from https://rethinkthc.com/research/thakur-2013-novel-adamantyl-cannabinoids-as
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.